Jeremy Grantham's RNA Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 15,444 shares of Atrium Therapeutics, Inc. (RNA) worth $206,486, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Jeremy Grantham has initiated a new position in RNA, representing a fresh investment thesis on this company. Largest reduction occurred in Q1 2026, reducing 139,011 shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Atrium Therapeutics (RNA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Atrium Therapeutics (RNA) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -139,011 | Reduce 90.00% | 15,444 | $13.37 |
| Q4 2025 | +154,455 | New Buy | 154,455 | $72.13 |
Jeremy Grantham's Atrium Therapeutics Investment FAQs
Jeremy Grantham first purchased Atrium Therapeutics, Inc. (RNA) in Q4 2025, acquiring 154,455 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Atrium Therapeutics, Inc. (RNA) for 2 quarters since Q4 2025.
Jeremy Grantham's largest addition to Atrium Therapeutics, Inc. (RNA) was in Q4 2025, adding 154,455 shares worth $11.14 M.
According to the latest 13F filing for Q1 2026, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 15,444 shares of Atrium Therapeutics, Inc. (RNA), valued at approximately $206,486.
As of the Q1 2026 filing, Atrium Therapeutics, Inc. (RNA) represents approximately 0.00% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Atrium Therapeutics, Inc. (RNA) was 154,455 shares, as reported at the end of Q4 2025.